We read with interest the letter by Mathian A et al1 describing the clinical course of COVID-19 in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. The COVID-19 Global Rheumatology Alliance registry2 shows that 19 (17%) of 110 patients with rheumatic diseases who have been diagnosed with COVID-19 as of 1 April 2020 were patients with lupus. Bozzalla Cassione et al,3 Romão et al4 and Ye et al,5 respectively, described patients with SLE in their papers. The latest paper by D’Silva et al reported ten cases of lupus in their cohort.6 We would like to share the clinical course of COVID-19 among patients with SLE in Malaysia.